Please login to the form below

Not currently logged in
Email:
Password:

Icon appoints Hugh Brady to board

He is former president of University College Dublin
ICON Hugh Brady

The contract research organisation (CRO) ICON has appointed Dr Hugh Brady to its board of directors.

Dr Brady is former president of University College Dublin (UCD) in Ireland, where he served from 2004 to 2013.

During this time he oversaw the expansion of the University's science, engineering and biomedical research capacity, including the development of several new research centres.

He also built links across the world, establishing the Beijing-Dublin International College and the UCD Shenzhen Health Sciences Institute in China.

In his role at Icon Dr Brady will be able to offer an in-depth knowledge of academia and research networks to Icon's efforts to support the pharma, biotech and medical device industries.

Thomas Lynch, chairman of Icon said: “His inspirational leadership of UCD, Irelands' largest university, during the past ten years, extensive international experience, especially in Asia, coupled with a distinguished career as an academic clinician in Ireland and the US will bring invaluable experience and expertise to Icon.”

2nd May 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics